战狼2

9月30日起 我国停止在全国疫苗接种计划下提供科兴疫苗_我的网站

A |     示意图。

B |     China's Ministry of Justice on Wednesday said that the European Union's (EU's) recent cross-border investigation into Chinese e-commerce giant JD.com under its Foreign Subsidies Regulation (FSR) has constituted unlawful extraterritorial jurisdiction.    The ministry said in a statement that no organization or individual may comply with or assist in implementing the EU's unlawful extraterritorial jurisdiction measures.    The ministry's statement came after the European Commission announced an investigation into JD.com's proposed takeover of German retailer Ceconomy in May.    In the statement, the ministry said the conclusion followed an investigation conducted under China's rules on countering foreign states' unlawful extraterritorial jurisdiction measures, which were issued in April this year.    According to the rules, the Chinese government has the authority to take countermeasures in response to extraterritorial jurisdiction measures by a foreign country that violate international law and the basic norms governing international relations and that harm China's sovereignty, security and development interests, or the legitimate rights and interests of Chinese citizens and organizations.    In May, citing the same set of rules, the ministry said that the EU's probe into Chinese security check company Nuctech constituted unlawful extraterritorial jurisdiction.    A spokesperson with the Ministry of Justice on Wednesday said the EU's probe, under the bloc's FSR effective since 2023, has arbitrarily demanded broad and unnecessary information located in China, which is a serious violation of the international rule of law.    "China will resolutely take countermeasures in accordance with the law if the EU side were to insist on the wrong course," the spokesperson said.    The spokesperson urged the EU to immediately correct its wrong practices, stop abusing the FSR as a tool, and foster a fair, impartial and predictable environment for companies investing and operating in the EU market.                    。（图：法新社）下个月30日起，我国将停止在全国疫苗接种计划下提供科兴冠病疫苗。卫生部的文告说，随着我国已经过渡到将冠病视为地方性流行病管理，卫生科学局要求所有冠病疫苗都必须全面注册，而不是在大流行期间紧急授权使用。

C | 文告说，由于中国研发的科兴疫苗没有向当局进行全面注册，我国将在停止在计划下提供这款疫苗。

D | 当局劝请有意接种这款疫苗的公众，最迟在下个月30日这么做。另外，文告也说，由于科兴疫苗已停止生产，本地市面上已无法购得这款疫苗，而私人诊所也无法通过特别采用程序（Special Access Route）提供这款疫苗。

E | 卫生部说，辉瑞-BioNTech生产的复必泰疫苗、莫德纳的Spikevax疫苗和诺瓦瓦克斯（Novavax）的Nuvaxovid疫苗都已向卫生科学局注册，因此会继续在全国疫苗接种计划下，提供给公众接种。文告说，冠病疫情会时不时出现，可能导致年长或体弱多病者患上重症。因此，卫生部劝请公众定期接种最新的冠病疫苗。

Current article:http://www.hanninhuaxituochunkui.pics/t28spv/20260826/7139168.htm

Published on:07:50:11